Articles On Creso Pharma (ASX:CPH)

The Creso Pharma Ltd (ASX: CPH) share price is on fire today. Shares are up 8% at the time of writing, having earlier posted intraday gains of more than 10%. Below we take a look at the latest product announcement from the ASX cannabis sha...

Biotechnology company Creso Pharma (ASX: CPH) has finalised the development of a hemp-derived feedstock known as Anibidoil Swine to support stress reduction and wellbeing in pigs. The Swiss-made flour and oat bran product has been designed...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

The Craft Designation award received by subsidiary Mernova in Ontario gives Creso Pharma product visibility throughout Canada. Global medicinal cannabis company, Creso Pharma (ASX:CPH), has announced that it was awarded a Craft Designation...

Craft designation is an important achievement for the company and is for a select few craft cannabis products that meet the criteria to qualify and are available for Ontario consumers.

In a development that will effectively make Creso Pharma Limited (ASX:CPH, FRA: 1X8) wholly-owned Canadian subsidiary Mernova Medicinal Inc. one of a select group of licensed cannabis producers the group has been awarded Craft Designation b...

Creso Pharma’s (ASX: CPH) Canadian subsidiary Mernova Medicinal Inc has been awarded craft designation by the Ontario Cannabis Store (OCS) for its Ritual Green cannabis products. Ritual Green is a small batch producer based in Nova Scotia w...

The CPH share price is down 2.6%. Creso Pharma Ltd [ASX:CPH] came out of a trading halt to announce its acquisition target Halucenex has upped its psilocybin inventory... The post Creso Pharma Share Price Dips on Halucenex Update (ASX:CPH)...

Creso Pharma (ASX: CPH)’s acquisition target Halucenex just picked up an extra 10g of ‘hard-to-access’ synthetic psilocybin - and now has 22.3g in total.

The additional supplies add to its existing inventory and allow the company to considerably ramp up proposed clinical trial and R&D initiatives

For Creso and Halucenex, the doubling of its supply of synthetic psilocybin has opened up options for future clinical trials and R&D initiatives. Global medicinal cannabis company, Creso Pharma (ASX:CPH), announced that its target acqui...

It has been a volatile morning for the Creso Pharma Ltd (ASX: CPH) share price after returning from a trading halt. After being up as much as 5.5% to 19 cents, the cannabis and psychedelics company’s shares are now down 9% to 16.3 cents. W...

Creso Pharma Limited (ASX:CPH, FRA:1X8) target acquisition company Halucenex Life Sciences has nearly doubled its supply of synthetic psilocybin. Halucenex has secured an additional 10 grams of synthetic psilocybin from its manufacturing pa...

Creso Pharma’s (ASX: CPH) soon-to-be subsidiary Halucenex Life Sciences has almost doubled its synthetic psilocybin supply as it gears up for a clinical trial and other research and development. In a market where synthetic psilocybin is har...

The ASX fell nearly 1 per cent today and below 7,000 index points as this week’s sell off continued. The ASX 200 closed at 6,983 points, which was 0.88 per cent lower than yesterday while the ASX Emerging Companies Index dropped 1.18 per ce...

While there appeared to be several winners out of Budget 2021, few of them were on the ASX. The ASX 200 fell for the second day in a row losing 0.73 per cent to close at 7,045 points. Meanwhile the ASX Emerging Companies Index fell 0.51 per...

The company has been granted a trading halt until the start of normal trading on Friday, May 14, 2021, or until an announcement is released to the market.

It will also provide CPH with the ability to develop and validate methods for potency, component identification and microbiology for botanical psilocybe mushrooms grown in the future at Halucenex.

Creso Pharma Limited (ASX:CPH, FRA:1X8) has today announced that its acquisition target Halucenex Life Sciences Inc. has signed an agreement with Nucro-Technics, a Pharmaceutical Contract Research Organization (CRO) that is a partner to pha...

Creso Pharma (ASX: CPH) target acquisition company Halucenex Life Sciences Inc has signed an agreement with Canadian pharmaceutical research firm Nucro-Technics to provide microbiology and chemistry test work for a salient delivery solution...

A cannabis-based drug has been listed on Australia’s Pharmaceutical Benefits Scheme for the first time, as medical marijuana gains increased acceptance. The move means that an estimated 116 Aussies with a rare form of epilepsy known as Drav...

The surge in revenue along with business ties-ups across major global markets following regulatory changes and the acquisition of an established psychedelics company could transform it into a broader-based pharma company.

With revenue rising by 237 per cent and strategic partnerships made during the quarter, Creso is now in pole position to fully launch into the US. Global medicinal cannabis company, Creso Pharma (ASX:CPH), has just released its quarterly up...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

There were several highlights to come out of the quarterly report released by Creso Pharma (ASX:CPH) today. CPH is enjoying a sustained run this year in the lead up to its US listing, which is expected to occur in the coming weeks. Highligh...

Creso Pharma (ASX: CPH) is listing on the US markets within weeks (via an OTC listing), but a similar company called MindMed is listing on the NASDAQ in 8 hours from now.

ASX pot stocks have run hot in recent months but eight in particular have been particularly rewarding for shareholders. Many pot stocks ran cold prior to COVID-19 as regulatory progress stalled and global markets didn’t take off. Australia...

April 20 has come and gone, but ASX cannabis companies aren’t getting that high — they’re actually low. Of the 36 pot companies in the space, 27 have lost ground over the last fortnight. Just seven have advanced. Gains were led by Wide Open...

The Creso Pharma Ltd [ASX:CPH] share price is trading flat despite updates on Halucenex and Californian legalisation of psychedelics. The CPH share price is down 1%... The post Creso Pharma Share Price is Flat on Halucenex Update (ASX:CPH)...

The collaboration with Sixth Wave Innovations Inc will provide an avenue to gain better understanding of the use of psychedelic compounds for a range of treatments and health benefits.

Halucencex’s partnership with Sixth Wave will fast track the research into hallucinogenic mushrooms, as California lifts bans on the product. Creso Pharma (ASX:CPH) target acquisition company, Halucencex Life Sciences, has just signed a non...

Creso Pharma Limited’s (ASX:CPH, FRA:1X8) target acquisition company Halucencex Life Sciences Inc. has signed a non-binding Letter of Intent (LOI) with leading nanotechnology company Sixth Wave Inc. The LOI comes as California pushes to dec...

As California moves to decriminalise psychedelics, Creso Pharma’s (ASX: CPH) soon-to-be subsidiary Halucenex Life Sciences has signed a letter of intent with Canadian listed Sixth Wave Innovations to work together on developing psilocybin s...

The agreement with Cannabis Queen, which has an established footprint and reputation, is expected to help drive growth and increase the visibility of Creso Pharma’s product in emerging markets.

Creso Pharma Limited (ASX:CPH; FRA: 1X8) has signed a bilateral commercial agreement with Cannabis Queen, South Africa to market and distribute Creso’s cannaDOL topical line and cannaQIX® tea range in African countries. As part of the agree...

Biotechnology company Creso Pharma (ASX: CPH) has signed a bilateral commercial agreement with South African skincare company Cannabis Queen to market and distribute its range of cannabidoil-based nutraceutical and tea products. Under the t...

The advisory agreement will allow Halucenex to gain a better understanding of components of psychedelic mushrooms, with data from sequencing expected to assist with treatment development initiatives and generating higher yield from extracti...

Special Report: Creso Pharma (ASX:CPH) says the Canadian psychedelic research company it has agreed to acquire is exploring sequencing the genome of hallucinogenic mushrooms to better understand what makes them so ‘magic’. Halucenex Life Sc...

Creso Pharma (ASX: CPH) target acquisition company Halucenex Life Sciences has entered into an advisory agreement with US-based biotechnology firm Growing Together Research Inc (GTR) to explore the genome sequencing of natural psilocybe, al...

Creso Pharma Limited (ASX:CPH, FRA:1X8) has provided an update regarding target acquisition company, Halucenex Life Sciences, outlining its entry into an advisory agreement with Growing Together Research Inc. (GTR) to explore the genome seq...

Source: Yarygin, Shutterstock Summary The Australian cannabis market is flourishing with growing patient numbers and better product selection. Medicinal cannabis player Bod Australia has won a new PO for CBD products for the US cannab...

The number of medical cannabis prescriptions issued under Australia’s special access scheme just keeps on growing. There were a record 9,959 SAS Category B marijuana prescriptions issued in March, two and a half times the number from a year...

Creso Pharma Limited’s (ASX:CPH; FRA: 1X8) wholly-owned Canadian subsidiary, Mernova Medicinal Inc. has secured new purchase orders valued at C$145,192 (A$150,770) from the Ontario Cannabis Store (OCS) and Yukon Liquor Corporation (Yukon)....

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on form again and charging higher. At the time of writing, the benchmark index is up 1.1% to 7,006.3 points. Four ASX shares that are climbing more than most today are listed be...

The Creso Pharma Ltd (ASX: CPH) share price is racing higher on Thursday following a positive announcement. At the time of writing, the cannabis company’s shares are up 6% to 20.7 cents. What did Creso announce? This morning Creso provided...

Creso Pharma’s (ASX: CPH) Canadian subsidiary Mernova has collared further purchase orders that include its Ritual Sticks pre-rolled joints and new one-ounce bag offering, which are both part of the wider Ritual Green cannabis product range...

With their mind blowing medical potential, are hallucinogens the next ASX ‘pot stock’ equivalent? By Tim Boreham, Editor, The New Criterion The mere mention of magic mushrooms, ecstasy or ketamine is enough to send parents of teenagers into...

Creso Pharma Ltd [ASX:CPH] hired a North American cannabis executive to expand its US business. Although Creso's update was seemingly positive, investors reacted by sending the CPH share price down 4.7% ... The post Creso Shares Down Despi...

The ASX picked up where it left off before the Easter break with another day of gains. The ASX 200 rose 0.84 per cent to 6,886 points and the ASX Emerging Companies Index rose 1.17 per cent, closing at 2,036 points. Utilities and energy wer...

The Creso Pharma Ltd (ASX: CPH) share price has come under pressure today despite the release of a positive announcement. At the time of writing, the cannabis company’s shares are down 5% to 20 cents. What did Creso Pharma announce? This m...